Two leaders in lipid nanoparticle (LNP) development have partnered to make PEG-free shielding lipids available to researchers advancing LNPs for non-viral drug delivery, gene therapy, mRNA vaccines, and biologic therapies.

Developed and manufactured at Curapath's headquarters in Valencia, Spain, Curapath's pSar lipids are synthetic biocompatible polymers that provide a non-toxic, non-immunogenic, and biodegradable alternative to PEGylated lipids with comparable efficacy in LNP formulations.

PEGylated lipids have traditionally been used to shield LNPs from immune detection but concerns about PEG-related immunogenicity and adverse reactions are prompting researchers to seek safer alternatives. Curapath's pSar shielding lipids address these challenges, providing researchers a safe and effective alternative to PEGylated lipids in LNPs.

Cayman brings together expertise in lipid chemistry, synthesis, and analysis to provide researchers with an extensive portfolio of lipids for LNP formulation. Partnering with innovators like Curapath strengthens Cayman's product portfolio and positions the company to provide cutting-edge solutions for LNP researchers.

At Curapath, we're proud to offer next-generation shielding lipids that address the growing need for safer, PEG-free alternatives in LNP formulation. This partnership with Cayman Chemical enables broader access to Curapath's proprietary polymers, empowering researchers worldwide to develop more effective and biocompatible therapies.